Skip to main content
European Commission logo print header

An integrated POC solution for non-invasive diagnosis and therapy monitoring of Heart Failure patients

Description du projet

Diagnostic salivaire de l’insuffisance cardiaque sur le lieu de soins

L’insuffisance cardiaque est un problème de santé mondial dont la prévalence augmente et dont le pronostic est peu favorable, alors que le diagnostic et le suivi thérapeutique souffrent d’un manque d’outils personnalisés et fiables. Pour relever ces défis, le projet KardiaTool, financé par l’UE, ambitionne de mettre au point un appareil portable capable de diagnostiquer l’insuffisance cardiaque et de surveiller le traitement sur le lieu de soins à partir d’échantillons de salive. Le dispositif intégrera différents biomarqueurs de l’insuffisance cardiaque à partir de la salive, proposant une alternative économique au dépistage sanguin. La facilité d’utilisation et le potentiel de surveillance continue que propose la solution KardiaTool devraient améliorer la pratique clinique et les soins prodigués aux patients souffrant d’insuffisance cardiaque.

Objectif

The aim of the KardiaTool project is to translate a laboratory proven concept of a saliva biosensor to the clinical practice for addressing the priority needs in personalized HF diagnostics and therapy monitoring at the point of care. The KardiaTool platform includes: (i) An easy to use portable POC device (KardiaPOC) with a disposable Lab-on-a-Chip (LOC), for the non-invasive, rapid and accurate qualitative and quantitative assessment of HF biomarkers, from saliva samples. KardiaPOC device will integrate a variety of sensors, actuators, Microelectromechanical systems (MEMS), micro-electronics, bio-chemicals and functionalized magnetic nanoparticles (MNPs), onto a disposable, low cost LOC. (ii) A decision support software (KardiaSoft) based on predictive modelling techniques, that analyzes the POC data and other patient’s data, directly added by the healthcare professionals, and delivers information related to HF diagnosis and therapy monitoring. The innovation lays in the incorporation of four novel saliva biomarkers that have been proven in a laboratory setting and bring a new promising concept for addressing the priority needs of the clinical arena. KardiaPOC will provide the capability of simultaneously extracting key information from the saliva biomarkers: (i) NT-proBNP, (ii) TNF-a, (iii) Interleukin- 10, (iv) Cortisol. It is expected that identifying a comparable source to blood, for biomarker information, such as saliva, that is cost effective, less invasive, more convenient and acceptable for both patients and healthcare professionals would be beneficial for the healthcare community. The challenge of KardiaTool is: (i) to translate a laboratory proven concept of a saliva biosensor into an MNBS platform, for HF diagnostics and therapy monitoring, at the point of care, following GLP (ii) to validate the MNBS platform through pre-clinical and clinical testing following GCP and (iii) to industrialize the outcomes following GMP towards progress to marketization

Appel à propositions

H2020-NMBP-2016-2017

Voir d’autres projets de cet appel

Sous appel

H2020-NMBP-X-KET-2017

Coordinateur

UNIVERSITE LYON 1 CLAUDE BERNARD
Contribution nette de l'UE
€ 446 132,43
Adresse
BOULEVARD DU 11 NOVEMBRE 1918 NUM43
69622 Villeurbanne Cedex
France

Voir sur la carte

Région
Auvergne-Rhône-Alpes Rhône-Alpes Rhône
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 446 132,43

Participants (16)